Celltrion, Foreign Investors Net Buy 404,684 Shares in Last 5 Days... Stock Price 296,500 Won (-0.34%)

As of 9:30 AM on the 15th, Celltrion is trading at 296,500 KRW, down 0.34% from the previous day. The trading volume is 553,643 shares, which is about 14.42% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.

On June 12, Kim Taehee, a researcher at Mirae Asset Daewoo, stated, "1) Celltrion maintains the number one market share in European biosimilars due to its rapid development speed, excellent clinical data, and strong marketing; 2) high performance growth is expected this year due to the recent launch of Truxima and Herzuma in the U.S.; and 3) the launch of Remsima SC in the second half of the year and a high-concentration Humira biosimilar next year will continue to drive new product effects, which are key investment points. We maintain our Top Pick opinion for the company’s bio/healthcare sector along with Celltrion Healthcare." The target price for Celltrion was set at 350,000 KRW.

Over the past five days, individual investors have net sold 121,467 shares of Celltrion, while foreigners and institutions have net bought 404,684 shares and net sold 255,029 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.